Clinical operations note: why-good-enough-beats-best-in-class-when-you-need-it-tomorrow-73

I’ll say it plain: Quality isn’t about picking the best product on paper.

After four years as a quality and brand compliance manager in the medical device space—reviewing roughly 200 unique items every year—I’ve landed on a view that surprises most of my colleagues: “Good enough” delivered with certainty often outperforms “best in class” that comes with a maybe.

Let me explain what I mean, because I know that sounds like heresy in an industry built on specs, tolerances, and clinical superiority claims.

What Globus Medical’s acquisition of Nevro taught me about reliability

In early 2025, when Globus Medical announced its acquisition of Nevro, a lot of the chatter focused on the product portfolio—spinal implants meeting neuromodulation capabilities. That’s all true. But from my seat in the quality trenches, the real story is about eliminating uncertainty in a high-stakes supply chain.

We’ve all seen it: a vendor promises a breakthrough device, but the lead time is “4–6 weeks, depending on regulatory clearance.” In a hospital setting, “depending on” is the enemy. Surgeons plan cases around equipment availability. If a spine implant system arrives a week late, it’s not just a scheduling inconvenience—it’s a canceled surgery, a delayed patient discharge, and potentially tens of thousands of dollars in lost revenue per case.

Globus built a reputation partly by offering a very broad product catalog—from surgical instruments to patient monitoring (ECG, pulse oximeter, ultrasound) to dental handpieces and energy devices. But what I hear from procurement managers is that the real differentiator is delivery consistency. They know, give or take a day, exactly when the pallet will show up.

I want to say our team’s satisfaction scores jumped 34% after we switched to vendors who prioritized reliability over spec upgrades—but don’t quote me on that exact number; I’d need to check the Q3 2024 audit report. (Should mention: we’d been burned by two “best in class” suppliers the year before, one of which missed a critical delivery for a spine navigation system by 11 days.)

When ‘best in class’ isn’t the right call

It’s tempting to think that the highest-spec product is always the best choice. But the “always buy premium” advice ignores a crucial nuance: context.

Take the question of a cardiac stent, for example. A hospital might have a choice between a new drug-eluting stent with slightly better patency rates (according to a single-center study) and a well-established model with 10 years of real-world data. The newer stent looks better on paper. But if that new stent has a 10-week lead time because the manufacturer is still ramping up production, and the established model is in stock with a 48-hour turnaround, which one actually serves the patient better?

I’ve seen procurement teams agonize over a 2% difference in a performance metric, only to lose the bigger battle on timing. In March 2024, we paid $400 extra for rush delivery of a custom surgical drill bit set. The alternative was missing a $15,000 surgical robot demo scheduled weeks earlier. The rush fee wasn’t about speed for its own sake—it was certainty. We knew the vendor could deliver Thursday if we paid the premium. The “standard delivery” option had a 40% historical on-time rate for that product line.

Simple math: $400 to secure a $15,000 event. Period.

A specific example: how a pulse oximeter spec nearly went sideways

Here’s a story that made the concept click for our team. In Q3 2023, we were evaluating suppliers for a large order of pulse oximeters—roughly 50,000 units annually. Vendor A offered a unit with a ±2% accuracy spec (very good) at $18 per unit. Vendor B offered ±3% accuracy at $15 per unit.

The purchasing manager wanted Vendor A. “Better accuracy, better patient outcomes,” she said. But when our quality team looked at the full picture, we found that Vendor A’s lead time was 12 weeks, and they’d been late on 35% of orders the previous year. Vendor B could deliver in 6 weeks, with a 92% on-time rate.

The surprise wasn’t the price difference—it was how much hidden value came with Vendor B. Their support team helped us verify CPT code mappings for reimbursement, which is something Globus also highlights as part of their regulatory and reimbursement support (FDA codes and payer documentation). That’s not just a nice-to-have; it directly affects how quickly hospitals get paid.

We went with Vendor B. In the first year, we saved roughly $150,000 on unit cost, avoided two stockouts that would have delayed surgical schedules, and cut procurement cycle time by 40%. The ±1% accuracy difference? In clinical practice, for the intended use (spot-check monitoring, not critical care), it was negligible.

Maybe I should add: we still use Vendor A for higher-acuity units where ±2% matters. Context, remember?

How this applies to Globus Medical and the broader market

Globus Medical’s competitive advantage isn’t that every product in their catalog is the absolute best in its category. It’s that they offer a dependable, broad portfolio that minimizes the risk of last-minute substitutions. For a hospital system juggling dozens of vendors, that’s gold.

Their ExcelsiusGPS navigation system isn’t the only robotic platform on the market. But if a hospital can bundle it with spine implants, surgical instruments, and imaging support—all from the same source with predictable delivery—the transaction cost drops dramatically. The vendor relationship becomes more valuable than any single spec advantage.

To be fair, mergers like Globus Nevro also carry integration risk. Two product lines, two quality systems, two regulatory pathways. But from what I’ve seen in similar acquisitions, the short-term disruption is often worth the long-term reliability gain—assuming the integration is done thoughtfully.

What I wish more procurement teams understood

It took me about 150 vendor evaluations and three years to understand this: a spec sheet doesn’t tell you what a product is like to buy.

Does the vendor answer emails within 4 hours? Do they flag delays before they happen? Can they handle a 2x surge order without falling apart? Do they help with billing codes?

These are the questions that separate a reliable partner from a paper tiger. Globus, for its part, has built a reputation on answering “yes” to those questions across a wide range of product categories—from electronic pipettes in a lab setting to large imaging systems in a hospital radiology suite.

Granted, there are times when only the best-in-class will do. For a complex cardiac stent placed in a critical vessel, you don’t compromise on performance data. But for the majority of purchasing decisions—where the difference between Good and Great is marginal in practice but significant in terms of availability—certainty wins.

Final thought: your worst missed opportunity is the one you see in hindsight

So glad I pushed for the Vendor B decision on those pulse oximeters. Almost caved to the “higher spec, always” crowd, which would have meant a 12-week wait and a 35% chance of delay. Dodged a bullet there.

If you’re a procurement manager or a surgeon evaluating equipment suppliers, I’d suggest asking two questions before any purchasing decision: “What happens if this product is late?” and “How certain am I about the delivery date?” If the answers scare you, maybe the “good enough” option that arrives on time is actually the better choice.

That’s not an excuse for low quality. It’s an argument for seeing quality as a system—where reliability, support, and timing matter just as much as the numbers in the brochure.